Open Access<p>pH-Responsive Fluorescence Enhanced Nanogel for Targeted Delivery of AUR and CDDP Against Breast Cancer</p>
Author(s) -
Zhiwen Cao,
Wen Li,
Rui Li,
Chenxi Li,
Yurong Song,
Guangzhi Liu,
Youwen Chen,
Cheng Lü,
Aiping Lu,
Yuanyan Liu
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s274842
Subject(s) - nanogel , in vivo , cisplatin , cytotoxicity , chemistry , pharmacology , paclitaxel , drug delivery , cancer cell , ic50 , cancer research , in vitro , cancer , chemotherapy , medicine , biochemistry , biology , microbiology and biotechnology , organic chemistry
Auraptene (AUR), a natural bioactive prenyloxy coumarin, is a highly pleiotropic molecule that can bind to the MT1 receptor and can effectively reduce the proliferation and migration of breast cancer cells. Cisplatin (CDDP), as the first synthetic platinum-based anticancer drug, is widely used in the clinic due to its definite mechanism and therapeutic effect on diverse tumors. However, both of AUR and CDDP exhibit some disadvantages when used alone, including poor solubility, low bioavailability, lack of selectivity and systemic toxicity when they are used singly.